Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA.
Leuk Res. 2010 May;34(5):594-7. doi: 10.1016/j.leukres.2009.08.029. Epub 2009 Sep 24.
Immunophenotypic identification of myeloid specific antigens is an important diagnostic tool in the management of patients with acute myeloid leukemia (AML). These antigens allow determination of cell of origin and degree of differentiation of leukemia blasts. AML with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) is a relatively rare subtype of AML. The immunophenotypic characteristics of inv(3) AML patients are somewhat limited. We identified 14 new cases of hematological disorders with increased myeloid blasts carrying inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Also, we identified another 13 cases previously published in the literature, where the immunophenotype of inv(3)(q21q26.2) was documented. As a group, patients with AML with inv(3)(q21q26.2) had high levels of early myeloid (CD13, CD33, CD117 and MPO) and uncommitted markers (CD34, HLA-DR and CD56) and a high rate of monosomy 7 in addition to the inv(3)(q21q26.2). Differential karyotype and expression of certain antigens were noted in patients with de novo AML with inv(3)(q21q26.2) vs. those with inv(3)(q21q26.2)-containing blasts.
髓系特异性抗原的免疫表型鉴定是急性髓系白血病(AML)患者管理的重要诊断工具。这些抗原可确定白血病原始细胞和分化程度。inv(3)(q21q26.2)/t(3;3)(q21;q26.2)的 AML 是一种相对罕见的 AML 亚型。inv(3)AML 患者的免疫表型特征有些受限。我们鉴定了 14 例新的伴有 inv(3)(q21q26.2)/t(3;3)(q21;q26.2)的髓系原始细胞增多的血液系统疾病病例。此外,我们还鉴定了文献中以前报道的另外 13 例病例,其中记录了 inv(3)(q21q26.2)的免疫表型。作为一组,inv(3)(q21q26.2)的 AML 患者具有高水平的早期髓系(CD13、CD33、CD117 和 MPO)和未分化标志物(CD34、HLA-DR 和 CD56),并且除了 inv(3)(q21q26.2)之外,还具有较高的单体 7 发生率。新发 inv(3)(q21q26.2)AML 患者与 inv(3)(q21q26.2)含有原始细胞的患者的核型和某些抗原的表达存在差异。